Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
Jessica Wenthe, Sedigheh Naseri, Ann-Charlotte Hellström, Rafael Moreno, Gustav Ullenhag, Ramón Alemany, Tanja Lövgren, Emma Eriksson, Angelica Loskog
Abstract
DCs, accompanied by a systemic increase of pro-inflammatory cytokines interferon γ (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin-27 (IL-27). This response was even more pronounced after combining the virus with checkpoint therapy, in particular with anti-PD-L1 and anti-TIM-3, leading to further reduced tumor growth in injected lesions. Moreover, anti-PD-L1 combination also facilitated abscopal responses in non-injected lesions.
Topics & Concepts
Priming (agriculture)Cancer researchImmune checkpointImmune systemGeneGenetic enhancementImmunotherapyBiologyMedicineImmunologyGeneticsBotanyGerminationCAR-T cell therapy researchVirus-based gene therapy researchImmunotherapy and Immune Responses